The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age.

Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants.

Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D.

Response to Haemophilus influenzae type B conjugate vaccine in children undergoing splenectomy.

Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine.

Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide.

Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine.

Antibody responses to four Haemophilus influenzae type b conjugate vaccines.

Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.

Hepatitis B surface antigen conjugate vaccine.

Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease.

Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group.

Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths.

Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region.

Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.

Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam.

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients.

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants.

Haemophilus influenzae type B conjugate vaccines.

Antibody response of 18 month old children 1 month and 18 months following Haemophilus influenzae type b vaccine administered singly or with DTP vaccine.

Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b.

Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.

Pediatric invasive Haemophilus influenzae infections in Israel in the era of Haemophilus influenzae type b vaccine: a nationwide prospective study.

Suggest Documents

Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants.

Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D.

Response to Haemophilus influenzae type B conjugate vaccine in children undergoing splenectomy.

Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine.

Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide.

Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine.

Antibody responses to four Haemophilus influenzae type b conjugate vaccines.

Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.

Hepatitis B surface antigen conjugate vaccine.

Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease.

Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group.

Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths.

Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region.

Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.

Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam.

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients.

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants.

Haemophilus influenzae type B conjugate vaccines.

Antibody response of 18 month old children 1 month and 18 months following Haemophilus influenzae type b vaccine administered singly or with DTP vaccine.

Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b.

Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.

Pediatric invasive Haemophilus influenzae infections in Israel in the era of Haemophilus influenzae type b vaccine: a nationwide prospective study.

The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age.

Recommend Documents

Follow Us